KAS
ADMA icon

Kemnay Advisory Services’s ADMA Biologics ADMA Stock Holding History

Kemnay Advisory Services’s Portfolio ADMA Stock Details ADMA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$17K Sell
2,027
-982
-33% -$8.95K ﹤0.01% 830
2026
Q1 		$27.1K Buy
3,009
+2,446
+434% +$38.6K ﹤0.01% 499
2025
Q4 		$10.3K Buy
+563
New +$9.49K ﹤0.01% 744

Other funds holding ADMA

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
RCMNY
Rubric Capital Management (New York) New York $10.9B AUM 70.31% 1-Year Est. Return
Capital Research Global Investors
Capital Research Global Investors Los Angeles, California $717B AUM 35.42% 1-Year Est. Return
First Trust Advisors
First Trust Advisors Wheaton, Illinois $170B AUM 46.21% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
CP
Caligan Partners New York $2.13B AUM 758.65% 1-Year Est. Return
D.E. Shaw & Co
D.E. Shaw & Co New York $210B AUM 57.28% 1-Year Est. Return

Kemnay Advisory Services's ADMA Position: Q2 2026 in Review

Kemnay Advisory Services reduced its ADMA Biologics (ADMA) stake by 33% in Q2 2026, selling an estimated $8.95K and leaving 2,027 shares worth $17K. The position accounts for ﹤0.01% of the portfolio, ranked #830.

Kemnay Advisory Services first reported a position in ADMA in Q4 2025 and has held it in 3 quarters since. The position peaked at $27.1K in Q1 2026. 322 funds tracked by Wall St. Rank hold ADMA as of Q2 2026.

  • Kemnay Advisory Services held 2,027 shares of ADMA Biologics worth $17K as of Q2 2026.
  • Kemnay Advisory Services sold 982 ADMA Biologics shares in Q2 2026, an estimated $8.95K.
  • ADMA Biologics made up ﹤0.01% of Kemnay Advisory Services's portfolio in Q2 2026, its #830 holding.
  • Kemnay Advisory Services first reported a position in ADMA Biologics in Q4 2025 and has held it in 3 quarters since.
  • Kemnay Advisory Services's ADMA Biologics position peaked at $27.1K in Q1 2026.
  • 322 funds tracked by Wall St. Rank held ADMA Biologics as of Q2 2026.

Based on Kemnay Advisory Services's 13F filing for Q2 2026, filed 14 Aug 2026.